Skip to main navigation Skip to search Skip to main content

Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial

  • Byram H Ozer
  • , Adam L Cohen
  • , Howard Colman
  • , Marta Penas-Prado
  • , John de Groot
  • , Monica E Loghin
  • , Edward Pan
  • , Jeffrey J Raizer
  • , Priya Kumthekar
  • , Karen L Fink
  • , Tobias Walbert
  • , Ryan T Merrell
  • , Morris D Groves
  • , Manmeet S Ahluwalia
  • , Jing Wu
  • , Eric C Burton
  • , Elizabeth Vera
  • , Tito Mendoza
  • , Ewa Grajkowska
  • , Kathleen Wall
  • Jennifer Reyes, Ying Yuan, Terri S Armstrong, Mark R Gilbert

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Glioblastoma (GBM) has limited effective salvage therapy options. The combination of the Type 1B topoisomerase/HIF1α inhibitor topotecan and the tyrosine kinase inhibitor pazopanib has shown promise in solid tumors and may be effective in recurrent GBM.

METHODS: Patients with recurrent GBM who were bevacizumab-naïve (Group A, 9 patients) or had previous bevacizumab (BEV) (Group B, 22 patients) started daily oral pazopanib (600 mg) and topotecan (0.25 mg). The primary objective was progression-free survival (PFS) at 6 months for Group A and 3 months for Group B patients. Secondary objectives included median progression-free and overall survival (OS), safety, tolerability, and toxicity as measured by patient-reported outcomes (PROs) and adverse event documentation.

RESULTS: Group A enrolled 9 evaluable patients and closed to accrual early when interim primary objectives were not met (PFS-6 11%). Group B enrolled 22 evaluable patients and narrowly met its primary objective (PFS-3 18%). Median PFS and OS endpoints demonstrated equivalent to slight improvement upon historical metrics, respectively. The regimen was tolerable and safe save for high frequency of hypertension, with PROs data showing stability or worsening in parallel with tumor stability or progression, respectively.

CONCLUSIONS: These findings suggest the regimen is safe and tolerable to GBM patients. The regimen was ineffective in bevacizumab-naïve patients and only narrowly met its predetermined endpoint in patients with prior BEV. These results do not support the combination regimen as tested in this protocol for further investigation in GBM.

Original languageEnglish
Pages (from-to)vdaf261
JournalNeuro-oncology advances
Volume8
Issue number1
DOIs
StatePublished - 2026
Externally publishedYes

Cite this